RT Journal Article
SR Electronic
T1 Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.15.20067157
DO 10.1101/2020.04.15.20067157
A1 Matthew J. Cummings
A1 Matthew R. Baldwin
A1 Darryl Abrams
A1 Samuel D. Jacobson
A1 Benjamin J. Meyer
A1 Elizabeth M. Balough
A1 Justin G. Aaron
A1 Jan Claassen
A1 LeRoy E. Rabbani
A1 Jonathan Hastie
A1 Beth R. Hochman
A1 John Salazar-Schicchi
A1 Natalie H. Yip
A1 Daniel Brodie
A1 Max R. O’Donnell
YR 2020
UL http://medrxiv.org/content/early/2020/04/20/2020.04.15.20067157.abstract
AB Background Nearly 30,000 patients with coronavirus disease-2019 (COVID-19) have been hospitalized in New York City as of April 14th, 2020. Data on the epidemiology, clinical course, and outcomes of critically ill patients with COVID-19 in this setting are needed.Methods We prospectively collected clinical, biomarker, and treatment data on critically ill adults with laboratory-confirmed-COVID-19 admitted to two hospitals in northern Manhattan between March 2nd and April 1st, 2020. The primary outcome was in-hospital mortality.Secondary outcomes included frequency and duration of invasive mechanical ventilation, frequency of vasopressor use and renal-replacement-therapy, and time to clinical deterioration following hospital admission. The relationship between clinical risk factors, biomarkers, and in-hospital mortality was modeled using Cox-proportional-hazards regression. Each patient had at least 14 days of observation.Results Of 1,150 adults hospitalized with COVID-19 during the study period, 257 (22%) were critically ill. The median age was 62 years (interquartile range [IQR] 51-72); 170 (66%) were male. Two-hundred twelve (82%) had at least one chronic illness, the most common of which were hypertension (63%; 162/257) and diabetes mellitus (36%; 92/257). One-hundred-thirty-eight patients (54%) were obese, and 13 (5%) were healthcare workers. As of April 14th, 2020, in-hospital mortality was 33% (86/257); 47% (122/257) of patients remained hospitalized. Two-hundred-one (79%) patients received invasive mechanical ventilation (median 13 days [IQR 9-17]), and 54% (138/257) and 29% (75/257) required vasopressors and renal-replacement-therapy, respectively. The median time to clinical deterioration following hospital admission was 3 days (IQR 1-6). Older age, hypertension, chronic lung disease, and higher concentrations of interleukin-6 and d-dimer at admission were independently associated with in-hospital mortality.Conclusions Critical illness among patients hospitalized with COVID-19 in New York City is common and associated with a high frequency of invasive mechanical ventilation, extra-pulmonary organ dysfunction, and substantial in-hospital mortality.Competing Interest StatementDr. Claassen is a minority shareholder at iCE Neurosystems. This does not relate to the current work. Dr. Brodie receives research support from ALung Technologies and he was previously on their medical advisory board. He has been on the medical advisory boards for Baxter, BREETHE, Xenios and Hemovent. None of these activities relate to the current work. Dr. O’Donnell is site principal investigator for clinical trials investigating the efficacy and safety of remdesivir in patients with moderate and severe COVID-19, sponsored by Gilead Sciences. All compensation is paid to Columbia University. The remaining authors have no interests to declare.Funding StatementThis work was supported by the U.S. National Institute of Allergy and Infectious Diseases [F32AI147528-01 to M.J.C]. No other external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author upon reasonable request.